Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with ...

A large study adds to evidence that the main ingredient in Novo Nordisk's injectable GLP-1 drug for type 2 diabetes may ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Semaglutide, the diabetes and weight loss drug that’s commonly known as Ozempic, can help patients of peripheral artery ...

ONE woman shared her experience on Ozempic after shedding a shocking amount of weight. She revealed that she dropped an ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Studies have shown that Ozempic not only lowers blood sugar and insulin levels but also improves cardiovascular outcomes. Clinical trials such as the SUSTAIN series have reported reduced risks of ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...